SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well vaccine therapy works when given
together with temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines
made from the survivin peptide or antigen may help the body build an effective immune
response to kill tumor cells that express survivin. Drugs used in chemotherapy, such as
temozolomide, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether temozolomide is more effective with or without vaccine therapy in treating
glioblastoma.